Various size polymers are obtained following glutaraldehyde treatment of native ovalbumin (OA). OA-POL, approximately 35 × 106 daltons, was prepared at the isoelectric point of OA. Treatment of CBA mice with microgram amounts of OA-POL led to efficient antigen-specific suppression of IgE responses. IgG anti-OA antibodies were not suppressed. Transfer of cells from OA-POL-treated donors into normal, unprimed recipients interfered with the ability of these animals to mount a primary or secondary IgE response. In addition, cotransfer of spleen cells from OA-POL-treated mice along with OA (in alum)-primed cells, into irradiated syngeneic recipients resulted in IgE class-specific suppression that was abrogated by treatment of OA-POL donor cells with monoclonal anti-Thy 1.2 + complement. The presence or absence of T cells in the OA-POL population had no effect on IgG levels in the recipients. Analysis of the antigenic properties of OA-POL revealed 5–15% cross-reactivity with native OA as perceived by IgG or IgE antibodies. In contrast, OA-POL was highly cross-reactive at the T cell level as shown functionally by its potent induction of OA-specific, IgE-selective suppressor T cells. The results suggest that the beneficial effects of glutaraldehyde-modified allergens, recently introduced in the immunotherapy of atopic individuals may be due to the preferential exposure on the polymerized protein, of antigenic determinants generating T suppressor cells and to the selective loss of B cell-reactive determinants.

This content is only available via PDF.
© 1983 S. Karger AG, Basel
1983
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.